Find an Article

Filter articles

Applied Filters

Showing 121 to 130 of 274 results

IP in the digital age: a tricky path ahead for pharma companies?

EU13-09-2016Stephen Bennett, Elisabethann Wright, Mark Marfe and James Cross

The pharmaceutical industry needs to adjust its expectations of the scope of IP protection available in the digital age, say Stephen Bennett, Elisabethann Wright and Mark Marfe of Hogan Lovells, and James Cross of RGC Jenkins.

SPCs and the unitary patent system: what now?

EU, UK06-09-2016Christopher Stothers and Paul Abbott

Brexit will have significant consequences for the UK regarding SPCs and the unitary patent system, while the UPC’s proposed start date of early 2017 looks highly unlikely, say Christopher Stothers and Paul Abbott of Arnold & Porter.

The pros and cons of second medical use

UK01-09-2016Clare Greatbanks

While we await the outcome of the appeal in Warner-Lambert v Actavis, which concerns second medical use patents, there are several steps drugs companies should take given the need to balance the interests of patent owners and generic makers. Clare Greatbanks of Osborne Clarke reports.

Brexit and life sciences: uncertainty reigns but change is on the way

EU, UK25-08-2016Christina Guazzi and Nina Schäffner

The consequences of the Brexit vote for the life sciences sector will depend on the UK’s relationship with the EU once the negotiations are concluded, as Christina Guazzi and Nina Schäffner of Freshfields Bruckhaus Deringer explain.

EPO opposition reforms: the changing face of central patent revocation

EU28-07-2016Stephanie Pilkington and Ling Zhuang

The European Patent Office has announced several reforms to its patent opposition procedures. Stephanie Pilkington and Ling Zhuang of Potter Clarkson consider some of their implications for centralised patent revocation in Europe from a life sciences perspective.

Under surveillance: generic and biosimilar MAs

EU26-07-2016Ruth Franken

In order to be well prepared before a generic or biosimilar marketing authorisation is approved, drugs companies in the EU may consider monitoring pending applications, says Ruth Franken of Hogan Lovells.

Running an efficient clinical drug trial

International19-07-2016Charlie Nicholson

Everyone benefits from an efficiently run clinical drug study, including sponsors, contract research organisations, the investigator sites where patients are treated and observed, and most of all, patients, says Charlie Nicholson of Premier Research.

Varying approaches: granting SPCs in Europe

EU, France, Germany, Spain, UK14-07-2016Simon Spink and Adrian Chew

For many of the key questions relating to the grant of SPCs, there is some variance in the practice of national patent offices, even where there is guidance from the CJEU, as Simon Spink and Adrian Chew of Bristows explain.

From the EU to Australia: latest SPC developments

Australia, EU07-07-2016Gareth Morgan

Legislative developments surrounding supplementary protection certificates in the EU are moving fast, and may be catching on as far afield as Australia. Gareth Morgan of Olswang explains more.

Brexit and IP: business as usual, for now

EU, UK07-07-2016Claire Phipps-Jones

Following the UK’s vote to leave the EU, it is business as usual for life sciences companies working with intellectual property, at least for now, says Claire Phipps-Jones of Bristows.

Showing 121 to 130 of 274 results